Showing 3541-3550 of 7628 results for "".
- FDA Approves Amendment to Avita's Vitiligo Trial Designhttps://practicaldermatology.com/news/fda-approves-amendment-to-avitas-vitiligo-trial-design/2460893/Avita Medical, Inc. will move forward with an amended pivotal clinical trial evaluating the safety and effectiveness of the RECELL® System for the repigmentation of stable vitiligo lesions to a streamlined single-arm trial design, now that the FDA has approved the trial modification. The
- Lilly's Lebrikizumab Performs Well in Two Phase 3 AD Trialshttps://practicaldermatology.com/news/lillys-lebrikizumab-performs-well-in-two-phase-3-ad-trials/2460892/Eli Lilly and Company's lebrikizumab led to significant improvements with at least 75 percent skin clearance in more than half of people with moderate-to-severe atopic dermatitis (AD), according to top-line results from ADvocate 1 and ADvocate 2. All primary and all key secondary en
- New Gel Shows Promise Against BCChttps://practicaldermatology.com/news/new-gel-shows-promise-against-bcc/2460890/Medivir AB’s topical histone deacetylase (HDAC) inhibitor remetinostat performed well in a phase II study in basal cell carcinoma (BCC), according to research published online in Clinical Cancer Research. The new gel could reduce the need for surgical
- New Survey: Americans Have Missed Out on Dating, Parties, School And Work Because of Acnehttps://practicaldermatology.com/news/new-survey-americans-have-missed-out-on-dating-parties-school-and-work-because-of-acne/2460889/Americans missed out on dating, school and hanging out with friends because of acne during the past year, according to a new survey by University Medical, the manufacturer of the Acne Wipeout skincare system. After more than a year of looking at themselves on screens and hiding behind s
- Patricia Treadwell, MD Assumes Presidency of Society for Pediatric Dermatologyhttps://practicaldermatology.com/news/patricia-treadwell-md-assumes-presidency-of-society-fir-pediatric-dermatology/2460888/Patricia Treadwell, MD is new President of the Society for Pediatric Dermatology (SPD). She assumed the role and the society and seated its new 2021-2022 Executive Committee members during the 46th Annual Conference last month. Dr. Treadwell is jo
- FDA Accepts Dermavant's NDA for Tapinarof Cream for the Treatment of Adults with Plaque Psoriasishttps://practicaldermatology.com/news/fda-accepts-dermavants-nda-for-tapinarof-cream-for-the-treatment-of-adults-with-plaque-psoriasis/2460886/The FDA has accepted Dermavant Sciences' New Drug Application (NDA) for tapinarof for the treatment of plaque psoriasis in adult patients. Tapinarof is an investigational, novel, therapeutic aryl hydrocarbon receptor modulating agent, in development as a once-daily, steroid-free and
- Vivacare Calls on Derms to Share Knowledge During Psoriasis Awareness Monthhttps://practicaldermatology.com/news/vivacare-calls-on-terms-to-share-knowledge-during-national-psoriasis-month/2460885/Dermatologists from around the country have contributed tips to Vivacare’s education resources and Physician Directory, and the company is inviting others to join in. In honor of Psoriasis Awareness Month, Vivacare is requesting dermatologists share insights regarding psoriasis and its trea
- Rinvoq Has Quicker Onset, Higher EASI Scores than Dupixent in Phase 3b Study of Adults with Atopic Dermatitishttps://practicaldermatology.com/news/rinvoq-bests-dupixent-in-phase-3b-study-of-adults-with-atopic-dermatitis/2460882/AbbVie’s JAK Inhibitor Rinvoq (upadacitinib) performed better than Dupixent (dupilumab) for primary and all ranked secondary endpoints in a phase 3b head-to-head study in adults with atopic dermatitis (AD), according to a
- Strand Therapeutics Scores Two Grants to Advance Programmable, Long-Lasting mRNA Therapeutics for Melanoma and Breast Cancerhttps://practicaldermatology.com/news/strand-therapeutics-scores-two-grants-to-advance-programmable-long-lasting-mrna-therapeutics-for-melanoma-and-breast-cancer/2460881/Strand Therapeutics was awarded two Phase I Small Business Innovation Research (SBIR) grants from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to develop mRNA-based therapeutics for melanoma and triple negative breast cancer (TNBC). The total fund
- Bausch Health Plans IPO of Solta Medical Aesthetics Unithttps://practicaldermatology.com/news/bausch-health-plans-ipo-of-solta-medical-aesthetics-unit/2460880/Bausch Health Companies Inc. is planning to pursue an initial public offering (IPO) of its Solta Medical business. Solta’s portfolio includes the Thermage RF systems, Fraxel laser, Clear + Brilliant laser and VASER ultrasonic systems. The timing of the anticipated IPO, w